Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Julphar
Accenture
Medtronic
Queensland Health
Merck
Chubb
Fuji
AstraZeneca

Generated: January 22, 2018

DrugPatentWatch Database Preview

PROCANBID Drug Profile

« Back to Dashboard

Which patents cover Procanbid, and when can generic versions of Procanbid launch?

Procanbid is a drug marketed by King Pharms and is included in one NDA.

The generic ingredient in PROCANBID is procainamide hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
Drug patent expirations by year for PROCANBID
Medical Subject Heading (MeSH) Categories for PROCANBID

US Patents and Regulatory Information for PROCANBID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-002 Jan 31, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-001 Jan 31, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PROCANBID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-002 Jan 31, 1996 ➤ Subscribe ➤ Subscribe
King Pharms PROCANBID procainamide hydrochloride TABLET, EXTENDED RELEASE;ORAL 020545-001 Jan 31, 1996 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
QuintilesIMS
Dow
Express Scripts
Cipla
McKesson
Accenture
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot